Tags

Type your tag names separated by a space and hit enter

Effect of Botulinum toxin A application in neuro-ophtalmologic indications on Schirmers test and tears osmolarity.
Cesk Slov Oftalmol 2019; 75(2):74-77CS

Abstract

Botulinum toxin type A (BT-A) is used in the treatment of neuro-ophthalmologic disorders such as essential blepharospasm and facial hemispasm for more than 20 years. Although the long-term effect of repeated application of the BT-A was confirmed, the BT-A effect on tears production and retention is not clear. In our work we investigated whether applied BT-A in patients with blepharospasm and hemifacial spasm affect tears production. Tears quality was measured with Schirmers and tear osmolarity test during neuro-ophthalmologic diseases treatment, which was evaluated before and 14 days after application of BT-A (Botox inj, Allergan, Irvine, USA) into the orbicularis oculi muscle. BT-A doses of 16-18 U with unilateral and 32 to 36 U bilateral applications were used. The mean tear production in Schirmers test before BT-A application was 8.38 ± 0.63 mm, and 2 weeks after BT-A application was 7.12 ± 0,6 mm (n = 50). Tear osmolarity was 305.4 ± 9.2 mOsm before BT-A application, and 2 weeks after BT-A application it was 305.2 ± 8,6 mOsm (n = 13). We found significant difference between two groups in tear quantity (p < 0.012), but not quality (p > 0.05). Application of the BT-A reduced the amount of tears measured by Schirmers test. These results confirm rational basis of the empirical clinical experience where an artificial tears substitution is recommended for patients with neuro-ophthalmologic disorders treated by BT-A.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31537075

Citation

Žiak, P, et al. "Effect of Botulinum Toxin a Application in Neuro-ophtalmologic Indications On Schirmers Test and Tears Osmolarity." Ceska a Slovenska Oftalmologie : Casopis Ceske Oftalmologicke Spolecnosti a Slovenske Oftalmologicke Spolecnosti, vol. 75, no. 2, 2019, pp. 74-77.
Žiak P, Halička J, Kapitánová K, et al. Effect of Botulinum toxin A application in neuro-ophtalmologic indications on Schirmers test and tears osmolarity. Cesk Slov Oftalmol. 2019;75(2):74-77.
Žiak, P., Halička, J., Kapitánová, K., & Mojžiš, P. (2019). Effect of Botulinum toxin A application in neuro-ophtalmologic indications on Schirmers test and tears osmolarity. Ceska a Slovenska Oftalmologie : Casopis Ceske Oftalmologicke Spolecnosti a Slovenske Oftalmologicke Spolecnosti, 75(2), pp. 74-77. doi:10.31348/2019/2/3.
Žiak P, et al. Effect of Botulinum Toxin a Application in Neuro-ophtalmologic Indications On Schirmers Test and Tears Osmolarity. Cesk Slov Oftalmol. 2019;75(2):74-77. PubMed PMID: 31537075.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of Botulinum toxin A application in neuro-ophtalmologic indications on Schirmers test and tears osmolarity. AU - Žiak,P, AU - Halička,J, AU - Kapitánová,K, AU - Mojžiš,P, PY - 2019/9/21/entrez KW - Schirmer’s test KW - Tear osmolarity KW - blepharospasm KW - botulinum toxin KW - dry eye KW - hemispasm SP - 74 EP - 77 JF - Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti JO - Cesk Slov Oftalmol VL - 75 IS - 2 N2 - Botulinum toxin type A (BT-A) is used in the treatment of neuro-ophthalmologic disorders such as essential blepharospasm and facial hemispasm for more than 20 years. Although the long-term effect of repeated application of the BT-A was confirmed, the BT-A effect on tears production and retention is not clear. In our work we investigated whether applied BT-A in patients with blepharospasm and hemifacial spasm affect tears production. Tears quality was measured with Schirmers and tear osmolarity test during neuro-ophthalmologic diseases treatment, which was evaluated before and 14 days after application of BT-A (Botox inj, Allergan, Irvine, USA) into the orbicularis oculi muscle. BT-A doses of 16-18 U with unilateral and 32 to 36 U bilateral applications were used. The mean tear production in Schirmers test before BT-A application was 8.38 ± 0.63 mm, and 2 weeks after BT-A application was 7.12 ± 0,6 mm (n = 50). Tear osmolarity was 305.4 ± 9.2 mOsm before BT-A application, and 2 weeks after BT-A application it was 305.2 ± 8,6 mOsm (n = 13). We found significant difference between two groups in tear quantity (p < 0.012), but not quality (p > 0.05). Application of the BT-A reduced the amount of tears measured by Schirmers test. These results confirm rational basis of the empirical clinical experience where an artificial tears substitution is recommended for patients with neuro-ophthalmologic disorders treated by BT-A. SN - 1211-9059 UR - https://www.unboundmedicine.com/medline/citation/31537075/Effect_of_Botulinum_toxin_A_application_in_neuro-ophtalmologic_indications_on_Schirmers_test_and_tears_osmolarity L2 - https://www.prolekare.cz/linkout/113078 DB - PRIME DP - Unbound Medicine ER -